Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

(2014) Markus Mandler et al.   ACTA NEUROPATHOLOGICA

Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

(2014) D. Games et al.   JOURNAL OF NEUROSCIENCE

ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo

(2014) Brian Spencer et al.   MOLECULAR THERAPY

Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease

(2014) Maciej Świątkiewicz et al.   Pharmacological Reports

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy

(2013) Elvira Valera et al.   GLIA

Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia

(2013) Changyoun Kim et al.   Nature Communications

Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage

(2013) G. K. Sheridan et al.   Open Biology

Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice

(2012) Darlene M. Rozewski et al.   AAPS Journal

Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein

(2012) Melanie B. Watson et al.   EXPERIMENTAL NEUROLOGY

Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia

(2012) Lisa Fellner et al.   GLIA

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

(2012) Yuan Xiao Zhu et al.   LEUKEMIA & LYMPHOMA

The many faces of α-synuclein: from structure and toxicity to therapeutic target

(2012) Hilal A. Lashuel et al.   NATURE REVIEWS NEUROSCIENCE

A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice

(2012) Marie-Francoise Chesselet et al.   Neurotherapeutics

Toll-Like Receptor 4 Promotes α-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons

(2011) Nadia Stefanova et al.   AMERICAN JOURNAL OF PATHOLOGY

Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates

(2011) Jodi A. Muscal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Use of ibuprofen and risk of Parkinson disease

(2011) X. Gao et al.   NEUROLOGY

In vivo demonstration that  -synuclein oligomers are toxic

(2011) B. Winner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity

(2010) Karin M. Danzer et al.   FASEB JOURNAL

Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies

(2010) He-Jin Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors

(2010) K. Ubhi et al.   JOURNAL OF NEUROSCIENCE

Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial

(2009) Elijah W. Stommel et al.   Amyotrophic Lateral Sclerosis

Lenalidomide (Revlimid®) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis

(2009) Arie Neymotin et al.   EXPERIMENTAL NEUROLOGY

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Thalidomide induced acute worsening of Parkinson's disease

(2009) Sara C. Crystal et al.   MOVEMENT DISORDERS

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of  -synuclein

(2009) P. Desplats et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Toll-like receptors in neurodegeneration

(2008) Eitan Okun et al.   BRAIN RESEARCH REVIEWS

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY